IOVA DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – IOVA

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Iovance Biotherapeutics, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on July 14, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Iovance securities between May 9, 2024, and May 8, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by July 14, 2025 [2]. - The lawsuit alleges that Iovance made false and misleading statements regarding the effectiveness of its sales team and new Authorized Treatment Centers (ATCs), which led to higher costs and lower revenue [3]. Group 2: Allegations Against Iovance - The lawsuit claims that new ATCs faced longer timelines to begin treating patients, and the sales team was ineffective in patient identification and selection, resulting in higher patient drop-offs [3]. - These dynamics contributed to a situation where ATCs could not keep pace with manufactured products, leading to misleading positive statements about Iovance's business and operations [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in recovering hundreds of millions for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including a notable settlement of over $438 million in 2019 [4].